| 摘要: |
| 目的:观察微创注入肺表面活性物质(PS)联合静脉注射地塞米松治疗早产儿支气管肺发育不良( BPD) 的疗效及安全
性。方法:回顾性分析2024 年1 月-2025 年1 月我院收治的90 例BPD 早产儿的临床资料,根据治疗方案分为对照组(44 例,微
创注入PS)和研究组(46 例,微创注入PS 联合静脉注射地塞米松)。比较治疗情况、血气指标、炎症指标、并发症发生情况。结
果:研究组的给氧时间、机械通气时间、住院时间较对照组短(P<0. 05)。治疗后,两组患儿的动脉血二氧化碳分压(PaCO2 )、肿
瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)水平低于治疗前,且研究组低于对照组(P<0. 05)。治疗后,两组患儿的动脉血氧
分压(PaO2 )高于治疗前,且研究组高于对照组(P<0. 05)。两组患儿并发症发生情况比较差异无统计学意义(P>0. 05)。结论:
微创注入PS 联合静脉注射地塞米松可缩短早产儿BPD 的给氧时间、机械通气时间、住院时间,改善血气指标,降低TNF-α、IL-8
水平,且未增加并发症。 |
| 关键词: 肺表面活性物质 地塞米松 早产儿 支气管肺发育不良 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2025.10.009 |
|
| 基金项目:保定市科学技术计划项目,编号2341ZF120。 |
|
| Efficacy and Safety of Minimally Invasive Administration of Pulmonary Surfactant Combined withIntravenous Injection of Dexamethasone in the Treatment of Bronchopulmonary Dysplasia in PrematureInfants |
| Zhang Chen, Xie Xuemin, Tian Fanglu, Wang Jiao |
| ((Baoding Maternal and Child Health Hospital, Hebei Baoding 071000,
China)) |
| Abstract: |
| Objective: To observe the efficacy and safety of minimally invasive administration of pulmonary surfactant (PS) combined
with intravenous injection of dexamethasone in the treatment of bronchopulmonary dysplasia (BPD) in premature infants. Methods:
Retrospective analysis was performed on clinical data of 90 premature infants with BPD admitted into our hospital from Jan. 2024 to Jan.
2025. According to different treatment methods, all patients were grouped into the control group (44 cases, minimally invasive
administration of PS) and study group (46 cases, minimally invasive administration of PS combined with intravenous injection of
dexamethasone). The treatment status, blood gas indicators, inflammation indicators, and complications were compared. Results: The
oxygen administration time, mechanical ventilation time and length of stay of study group were shorter than those of control group (P<
0. 05). After treatment, the arterial partial pressure of carbon dioxide (PaCO2 ), tumor necrosis factor-α (TNF-α), and interleukin-8
(IL-8) in both groups were lower than those before treatment, and the study group was lower than the control group (P<0. 05). After
treatment, the arterial partial pressure of oxygen (PaO2 ) in both groups was higher than that before treatment, and the study group was
higher than the control group (P<0. 05). There was no statistically significant difference in the occurrence of complications between two
groups (P >0. 05). Conclusion: Minimally invasive administration of PS combined with intravenous injection of dexamethasone for
premature infants with BPD can shorten the oxygen administration time, mechanical ventilation time, length of stay, improve blood gas
indicators, and reduce TNF-α and IL-8 levels without increasing the complications. |
| Key words: pulmonary surfactant dexamethasone premature infants bronchopulmonary dysplasia |
